Institutional investors purchased a net $2.3 million shares of VICL during the quarter ended March 2013. This may signal that the smart money is gaining interest in this company as the 46.87% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
| Mutual fund holders | 29.22% |
| Individual stakeholders | 22.80% |
| Other institutional | 17.65% |